



Current Partnering



BROCHURE: Partnering Agreements with BigPharma

Bigpharma company profiles
Company – therapy activity finder
Partnering contact listings
Key networking events
Top M&A and partnering deals by value
Most active bigpharma dealmakers
Bigpharma partnering contracts

Publication date: February 2010

Report code: CP1010

Version: 2

www.currentpartnering.com

Report description

The **Partnering Agreements with Bigpharma** report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

This premier report provides all the information you require to better understand bigpharma partnering.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 200 charts allow quick understanding of each bigpharma companies dealmaking trends over the last four years.

This report contains over 1,200 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

Contract documents provide the answers to numerous questions about a prospective partner's flexibility on a wide range of important issues, many of which will have a significant impact on each party's ability to derive value from the deal.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues and dealmaking activity since 2005.

Chapter 3 analyzes the most active dealmakers since 2005 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-9 according to reported deal size.

Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 7 and 8.

Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last three years.

Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company's marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.

In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which links direct to an online copy of the actual contract document as filed with the SEC.

Key benefits

Partnering Agreements with Bigpharma provides the user with the following key benefits:

- Detailed company profiles for each of the top 50 bigpharma companies
- Over 200 charts showing a company's dealmaking activity since 2005, allowing quick identification potential partners
- In-depth marketed and pipeline product activity of each company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 – number of deals per year
- Partnering activity for 2005-2009
 - Activity by deal type
 - Activity by phase of development
 - Activity by therapeutic area
 - List of recent partner companies
- Comprehensive access to over 1,200 actual contracts entered into by the leading fifty biopharma companies
- Insight into the terms included in a partnering agreement, together with real world clause examples
- Understand the key deal terms the company has agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

Partnering Agreements with Bigpharma is intended to provide the reader with an in-depth understanding of the partnering activities and interests of the leading fifty biopharma companies worldwide, enabling the effective assessment and selection of partners of choice, based on the latest knowledge of a company's approach to partnering.

Partnering Agreements with Bigpharma includes:

- Detailed company profiles for each of the top 50 bigpharma companies, including:
 - Full contact details
 - Business developer contact details including name, title, email and telephone (where available)
 - Marketed indications
 - Pipeline indications
 - Partnering interests and indications
 - Partnering activity since 2000
 - Current partner companies since 2005
 - Partnering activity since 2005 by:
 - Deal type
 - Stage of development
 - Therapy area
- Over 200 charts showing the dealmaking activity of each company since 2005
- The tools to enable effective and efficient preparation for partnering negotiation with bigpharma
- Listing of over 1,200 contract documents between bigpharma and partner companies
- The leading M&A and partnering deals by value 2005-9
- Most active M&A and partnering dealmakers 2005-9



Current Partnering

Best practice for dealmakers

The **Partnering Agreements with Bigpharma** report also provides comprehensive access to available contract documents for each of the fifty bigpharma companies. Analyzing actual company agreements allows assessment of the following:

- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?

For each company in **Partnering Agreements with Bigpharma** report, the available contracts are listed by deal type, including:

- Co-development
- Co-marketing
- Co-promotion
- Collaborative R&D
- Development
- Distribution
- Joint venture
- Licensing
- M&A
- Manufacturing
- Marketing
- Promotion
- Research
- Supply

Number of pages:

The report is comprised of 655 pages.

Executive Summary

Welcome to the **Partnering Agreements with Bigpharma**, the definitive guide to biopharma partnering interests, contacts and contracts.

The **Partnering Agreements with Bigpharma** report provides the most comprehensive and in-depth insight into the dealmaking interests and activity of the worlds leading fifty biopharma companies.

One of the key aspects of partnering is finding those companies that are potential candidates for the development and commercialization of the next generation of therapies. A lot of resources are spent on finding partners, identifying their interests and making contact to initiate discussions.

Using this report, dealmakers will effectively and efficiently target their partnering activities to deliver the company's business development objectives. Over 200 charts allow quick understanding of each biopharma companies dealmaking trends over the last four years.

The initial chapters of this report provide an orientation of bigpharma's dealmaking and business activities.

Chapter 1 provides an introduction to the report, whilst chapter 2 lists the top 50 leading biopharma companies based on 2008 pharmaceutical revenues and dealmaking activity since 2005.

Chapter 3 analyzes the most active dealmakers since 2005 in M&A and partnering deals announced, whilst chapter 4 analyzes the top deals of 2005-9 according to reported deal size.

Chapter 5 provides a summary on best practice on how to submit an opportunity to bigpharma, to ensure building of relationships and to obtain a prompt assessment and response from the business development function of the prospective partner.

Chapter 6 lists forthcoming partnering events where valuable face to face meetings with bigpharma provide a highly effective means of obtaining interest in novel opportunities. These events are where dealmaking gets initiated through numerous back to back meetings.

The main body of the report is provided in chapter 7 and 8.

Firstly, a series of matrices provide a cross reference for each bigpharma company versus therapy area with respect to marketed and pipeline activity, partnering interests, and partnering activity in the last two years.

Secondly, in-depth profiles of every bigpharma company provide everything required to assess the suitability of a company as a prospective partner. This includes a company overview, detailed analysis of the company's marketed and pipeline disease targets, partnering interests, partnering activity according to deal type, phase of development, therapy area. Each profile also includes in-depth contact information for individuals within the business development function.

In addition, each company profile provides a listing of deal contract documents available in the public domain, each of which links direct to an online copy of the actual contract document as filed with the SEC.

One of the key aspects of partnering is conducting due diligence on a partner to determine under what terms a prospective partner agrees to a partnering relationship.

Understanding the flexibility of a prospective partners' negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how

payments are triggered – contract documents provide this insight where press releases and databases do not.

This report contains over 1,000 links to online copies of actual contract documents as submitted to the Securities Exchange Commission by bigpharma and their partners.

In addition, contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each parties ability to derive value from the deal.

In summary, the report provides the reader with the tools necessary to make successful contact with the right bigpharma partners effectively and efficiently:

- Detailed company profile for the top 50 bigpharma
- In-depth marketed and pipeline product activity of each company
- Partnering interests and therapy focus revealed
- Partnering activity since 2000 – number of deals per year
- Partnering activity for 2005-2008
 - Activity by deal type
 - Activity by phase of development
 - Activity by therapeutic area
 - List of recent partner companies
- Direct contact information for over 1,000 bigpharma dealmakers – name, title, email, telephone details, where available
- General company and partnering contact information
- List of contract documents available to allow analysis of bigpharma deal terms – each linked to an online copy of the actual contract as filed at the SEC.



Table of contents

Executive Summary

Chapter 1 – Introduction

Chapter 2 – Bigpharma top 50 and their dealmaking activity

Chapter 3 – Most active bigpharma dealmakers

3.1 Bigpharma M&A activity

3.2 Bigpharma partnering

Chapter 4 – Top bigpharma deals by value

4.1 Bigpharma M&A

4.2 Bigpharma partnering

Chapter 5 – Submitting Opportunities to Bigpharma

5.1 How to submit an opportunity

5.2 Opportunity submission template

5.3 Sending emails

5.4 Face to face at partnering events

5.5 Online submission forms

Chapter 6 – Forthcoming bigpharma partnering events

6.1 Forthcoming events

Chapter 7 – Bigpharma company – therapy locator

7.1 How to use the therapy matrix tables

7.2 Therapeutic area definitions

7.3 Bigpharma – Therapeutic target matrix – marketed and pipeline compounds

7.4 Bigpharma – Therapeutic target matrix – expressed partnering interests

7.5 Bigpharma – Therapeutic target matrix – recent deals – 2005-2009

Chapter 8 – Bigpharma Company Profiles

8.1 How to use company profiles

8.2 Field definitions

8.3 Company profiles

Abbott

Actavis

Alcon Labs

Allergan

Amgen

Astellas

AstraZeneca

Baxter

Bayer
Biogen Idec
Boehringer Ingelheim
Bristol-Myers Squibb
Cephalon
Chugai
CSL
Daiichi Sankyo
Dainipon Sumitomo
Eisai
Eli Lilly
Forest Laboratories
Genentech
Genzyme
Gilead Sciences
GlaxoSmithKline
Hospira
Johnson & Johnson
Lundbeck
Menarini
Merck & Co
Merck Serono
Mitsubishi-Tanabe
Mylan
Novartis
Novo Nordisk
Nycomed Pharma
Otsuka
Pfizer
Procter & Gamble
Ratiopharm
Roche
Sanofi-Aventis
Schering Plough
Servier
Shire
Solvay
Takeda
Teva
UCB
Watson
Wyeth

Chapter 9 – Resources

Appendices

Appendix 1 – Example contract document
About CurrentPartnering
Recent titles from CurrentPartnering
Order Form – Reports
Order Form – Partnering Agreements Company Profiles 2010

Table of figures

- Figure 1: Bigpharma – top 50 by pharma sales
- Figure 2: Leading Bigpharma M&A companies, 2005-2009
- Figure 3: Bigpharma M&A activity – top 50 by pharma sales
- Figure 4: Leading Bigpharma partnering companies, 2005-2009
- Figure 5: Bigpharma partnering activity – top 50 by pharma sales
- Figure 6: Leading M&A deals involving bigpharma by value, 2005-2009
- Figure 7: Leading partnering deals by value, 2005-2009
- Figure 8: Typical partnering opportunity submission template
- Figure 10: Therapeutic area definitions 36
- Figure 11: Therapeutic target matrix – marketed and pipeline compounds
- Figure 12: Therapeutic target matrix – expressed partnering interests
- Figure 12: Therapeutic target matrix – recent deals 2005-2009
- Figure 14: Company profile template and definitions used in report
- Figure 15: Abbott – Dealmaking frequency 2000-2009
- Figure 16: Abbott - recent deals (2005-2009) by deal type
- Figure 17: Abbott - recent deals (2005 – 2009) by stage of development
- Figure 18: Abbott – recent deals (2005 – 2009) by therapy area
- Figure 19: Recent Abbott partnering deals (2003-2009) where contract document available
- Figure 20: Actavis – Dealmaking frequency 2000-2009
- Figure 21: Actavis - recent deals (2005-2009) by deal type
- Figure 22: Actavis - recent deals (2005 – 2009) by stage of development
- Figure 23: Actavis – recent deals (2005 – 2009) by therapy area
- Figure 24: Recent Actavis partnering deals (2003-2009) where contract document available
- Figure 25: Alcon Labs dealmaking frequency 2000-2009
- Figure 26: Alcon Labs - recent deals (2005 - 2009) by deal type
- Figure 27: Alcon Labs - recent deals (2005 – 2009) by stage of development
- Figure 28: Alcon Labs – recent deals (2005 – 2009) by therapy area
- Figure 29: Recent Alcon Labs partnering deals (2003-2009) where contract document available
- Figure 30: Allergan – Dealmaking frequency 2000-2009
- Figure 31: Allergan - recent deals (2005-2009) by deal type
- Figure 32: Allergan - recent deals (2005 – 2009) by stage of development
- Figure 33: Allergan – recent deals (2005 – 2009) by therapy area
- Figure 34: Recent Allergan partnering deals (2003-2009) where contract document available
- Figure 35: Amgen – Dealmaking frequency 2000-2009
- Figure 36: Amgen - recent deals (2005-2009) by deal type
- Figure 37: Amgen - recent deals (2005 – 2009) by stage of development
- Figure 38: Amgen – recent deals (2005 – 2009) by therapy area
- Figure 39: Recent Amgen partnering deals (2003-2009) where contract document available
- Figure 40: Astellas – Dealmaking frequency 2000-2009
- Figure 41: Astellas - recent deals (2005-2009) by deal type
- Figure 42: Astellas - recent deals (2005 – 2009) by stage of development
- Figure 43: Astellas – recent deals (2005 – 2009) by therapy area
- Figure 44: Recent Astellas partnering deals (2003-2009) where contract document available
- Figure 45: AstraZeneca – Dealmaking frequency 2000-2009
- Figure 46: AstraZeneca - recent deals (2005-2009) by deal type
- Figure 47: AstraZeneca - recent deals (2005 – 2009) by stage of development
- Figure 48: AstraZeneca – recent deals (2005 – 2009) by therapy area
- Figure 49: Recent AstraZeneca partnering deals (2003-2009) where contract document available
- Figure 50: Baxter – Dealmaking frequency 2000-2009
- Figure 51: Baxter - recent deals (2005-2009) by deal type
- Figure 52: Baxter - recent deals (2005 – 2009) by stage of development
- Figure 53: Baxter – recent deals (2005 – 2009) by therapy area
- Figure 54: Recent Baxter partnering deals (2003-2009) where contract document available
- Figure 55: Bayer – Dealmaking frequency 2000-2009

Figure 56: Bayer - recent deals (2005-2009) by deal type
Figure 57: Bayer - recent deals (2005 – 2009) by stage of development
Figure 58: Bayer – recent deals (2005 – 2009) by therapy area
Figure 59: Recent Bayer partnering deals (2003-2009) where contract document available
Figure 60: Biogen Idec – Dealmaking frequency 2000-2009
Figure 61: Biogen Idec - recent deals (2005 – 2009) by deal type
Figure 62: Biogen Idec - recent deals (2005 – 2009) by stage of development
Figure 63: Biogen Idec – recent deals (2005 – 2009) by therapy area
Figure 64: Recent Biogen Idec partnering deals (2003-2009) where contract document available
Figure 65: Boehringer Ingelheim – Dealmaking frequency 2000-2009
Figure 66: Boehringer Ingelheim - recent deals (2005 – 2009) by deal type
Figure 67: Boehringer Ingelheim - recent deals (2005 – 2009) by stage of development
Figure 68: Boehringer Ingelheim – recent deals (2005 – 2009) by therapy area
Figure 69: Recent Boehringer Ingelheim partnering deals (2003-2009) where contract document available
Figure 70: Bristol-Myers Squibb – Dealmaking frequency 2000-2009
Figure 71: Bristol-Myers Squibb - recent deals (2005 – 2009) by deal type
Figure 72: Bristol-Myers Squibb - recent deals (2005 – 2009) by stage of development
Figure 73: Bristol-Myers Squibb – recent deals (2005 – 2009) by therapy area
Figure 74: Recent Bristol-Myers Squibb partnering deals (2003-2009) where contract document available
Figure 75: Cephalon – Dealmaking frequency 2000-2009
Figure 76: Cephalon - recent deals (2005-2009) by deal type
Figure 77: Cephalon - recent deals (2005 – 2009) by stage of development
Figure 78: Cephalon – recent deals (2005 – 2009) by therapy area
Figure 79: Recent Cephalon partnering deals (2003-2009) where contract document available
Figure 80: Chugai – Dealmaking frequency 2000-2009
Figure 81: Chugai - recent deals (2005-2009) by deal type
Figure 82: Chugai - recent deals (2005 – 2009) by stage of development
Figure 83: Chugai – recent deals (2005 – 2009) by therapy area
Figure 84: Recent Chugai partnering deals (2003-2009) where contract document available
Figure 85: CSL – Dealmaking frequency 2000-2009
Figure 86: CSL - recent deals (2005-2009) by deal type
Figure 87: CSL - recent deals (2005 – 2009) by stage of development
Figure 88: CSL – recent deals (2005 – 2009) by therapy area
Figure 89: Recent CSL partnering deals (2003-2009) where contract document available
Figure 90: DaiichiSankyo – Dealmaking frequency 2000-2009
Figure 91: DaiichiSankyo - recent deals (2005-2009) by deal type
Figure 92: DaiichiSankyo - recent deals (2005 – 2009) by stage of development
Figure 93: DaiichiSankyo – recent deals (2005 – 2009) by therapy area
Figure 94: Recent DaiichSankyo partnering deals (2003-2009) where contract document available
Figure 95: Dainippon Sumitomo – Dealmaking frequency 2000-2009
Figure 96: Dainippon Sumitomo - recent deals (2005-2009) by deal type
Figure 97: Dainippon Sumitomo - recent deals (2005 – 2009) by stage of development
Figure 98: Dainippon Sumitomo – recent deals (2005 – 2009) by therapy area
Figure 99: Recent Dainippon Sumitomo partnering deals (2003-2009) where contract document available
Figure 100: Eisai – Dealmaking frequency 2000-2009
Figure 101: Eisai - recent deals (2005-2009) by deal type
Figure 102: Eisai - recent deals (2005 – 2009) by stage of development
Figure 103: Eisai – recent deals (2005 – 2009) by therapy area
Figure 104: Recent Eisai partnering deals (2003-2009) where contract document available
Figure 105: Eli Lilly – Dealmaking frequency 2000-2009
Figure 106: Eli Lilly - recent deals (2005-2009) by deal type
Figure 107: Eli Lilly - recent deals (2005 – 2009) by stage of development
Figure 108: Eli Lilly – recent deals (2005 – 2009) by therapy area
Figure 109: Recent Eli Lilly partnering deals (2003-2009) where contract document available
Figure 110: Forest – Dealmaking frequency 2000-2009
Figure 111: Forest - recent deals (2005-2009) by deal type
Figure 112: Forest - recent deals (2005 – 2009) by stage of development
Figure 113: Forest – recent deals (2005 – 2009) by therapy area
Figure 114: Recent Forest partnering deals (2003-2009) where contract document available

Figure 115: Genentech – Dealmaking frequency 2000-2009
Figure 116: Genentech - recent deals (2005-2009) by deal type
Figure 117: Genentech - recent deals (2005 – 2009) by stage of development
Figure 118: Genentech – recent deals (2005 – 2009) by therapy area
Figure 119: Recent Genentech partnering deals (2003-2009) where contract document available
Figure 120: Genzyme – Dealmaking frequency 2000-2009
Figure 121: Genzyme - recent deals (2005-2009) by deal type
Figure 122: Genzyme - recent deals (2005 – 2009) by stage of development
Figure 123: Genzyme – recent deals (2005 – 2009) by therapy area
Figure 124: Recent Genzyme partnering deals (2003-2009) where contract document available
Figure 125: Gilead – Dealmaking frequency 2000-2009
Figure 126: Gilead - recent deals (2005-2009) by deal type
Figure 127: Gilead - recent deals (2005 – 2009) by stage of development
Figure 128: Gilead – recent deals (2005 – 2009) by therapy area
Figure 129: Recent Gilead partnering deals (2003-2009) where contract document available
Figure 130: GlaxoSmithKline – Dealmaking frequency 2000-2009
Figure 131: GlaxoSmithKline - recent deals (2005-2009) by deal type
Figure 132: GlaxoSmithKline - recent deals (2005 – 2009) by stage of development
Figure 133: GlaxoSmithKline – recent deals (2005 – 2009) by therapy area
Figure 134: Recent GlaxoSmithKline partnering deals (2003-2009) where contract document available
Figure 135: Hospira – Dealmaking frequency 2000-2009
Figure 136: Hospira - recent deals (2005-2009) by deal type
Figure 137: Hospira - recent deals (2005 – 2009) by stage of development
Figure 138: Hospira – recent deals (2005 – 2009) by therapy area
Figure 139: Recent Hospira partnering deals (2003-2009) where contract document available
Figure 140: Johnson & Johnson – Dealmaking frequency 2000-2009
Figure 141: Johnson & Johnson - recent deals (2005-2009) by deal type
Figure 142: Johnson & Johnson - recent deals (2005 – 2009) by stage of development
Figure 143: Johnson & Johnson – recent deals (2005 – 2009) by therapy area
Figure 144: Recent Johnson & Johnson partnering deals (2003-2009) where contract document available
Figure 145: Lundbeck – Dealmaking frequency 2000-2009
Figure 146: Lundbeck - recent deals (2005-2009) by deal type
Figure 147: Lundbeck - recent deals (2005 – 2009) by stage of development
Figure 148: Lundbeck – recent deals (2005 – 2009) by therapy area
Figure 149: Recent Lundbeck partnering deals (2003-2009) where contract document available
Figure 150: Menarini – Dealmaking frequency 2000-2009
Figure 151: Menarini - recent deals (2005-2009) by deal type
Figure 152: Menarini - recent deals (2005 – 2009) by stage of development
Figure 153: Menarini – recent deals (2005 – 2009) by therapy area
Figure 154: Recent Menarini partnering deals (2003-2009) where contract document available
Figure 155: Merck & Co – Dealmaking frequency 2000-2009
Figure 156: Merck & Co - recent deals (2005-2009) by deal type
Figure 157: Merck & Co - recent deals (2005 – 2009) by stage of development
Figure 158: Merck & Co – recent deals (2005 – 2009) by therapy area
Figure 159: Recent Merck & Co partnering deals (2003-2009) where contract document available
Figure 160: Merck KGaA – Dealmaking frequency 2000-2009
Figure 161: Merck KGaA - recent deals (2005-2009) by deal type
Figure 162: Merck KGaA - recent deals (2005 – 2009) by stage of development
Figure 163: Merck KGaA – recent deals (2005 – 2009) by therapy area
Figure 164: Recent Merck KGaA partnering deals (2003-2009) where contract document available
Figure 165: Mitsubishi-Tanabe – Dealmaking frequency 2000-2009
Figure 166: Mitsubishi-Tanabe - recent deals (2005-2009) by deal type
Figure 167: Mitsubishi-Tanabe - recent deals (2005 – 2009) by stage of development
Figure 168: Mitsubishi-Tanabe – recent deals (2005 – 2009) by therapy area
Figure 169: Recent Mitsubishi-Tanabe partnering deals (2003-2009) where contract document available
Figure 170: Mylan – Dealmaking frequency 2000-2009
Figure 171: Mylan - recent deals (2005-2009) by deal type
Figure 172: Mylan - recent deals (2005 – 2009) by stage of development
Figure 173: Mylan – recent deals (2005 – 2009) by therapy area

Figure 174: Recent Mylan partnering deals (2003-2009) where contract document available
Figure 175: Novartis – Dealmaking frequency 2000-2009
Figure 176: Novartis - recent deals (2005-2009) by deal type
Figure 177: Novartis - recent deals (2005 – 2009) by stage of development
Figure 178: Novartis – recent deals (2005 – 2009) by therapy area
Figure 179: Recent Novartis partnering deals (2003-2009) where contract document available
Figure 180: Novo Nordisk – Dealmaking frequency 2000-2009
Figure 181: Novo Nordisk - recent deals (2005-2009) by deal type
Figure 182: Novo Nordisk - recent deals (2005 – 2009) by stage of development
Figure 183: Novo Nordisk – recent deals (2005 – 2009) by therapy area
Figure 184: Recent Novo Nordisk partnering deals (2003-2009) where contract document available
Figure 185: Nycomed – Dealmaking frequency 2000-2007
Figure 186: Nycomed - recent deals (2005-2008) by deal type
Figure 187: Nycomed - recent deals (2005 – 2009) by stage of development
Figure 188: Nycomed – recent deals (2005 – 2009) by therapy area
Figure 189: Recent Nycomed partnering deals (2003-2009) where contract document available
Figure 190: Otsuka – Dealmaking frequency 2000-2009
Figure 191: Otsuka - recent deals (2005-2009) by deal type
Figure 192: Otsuka - recent deals (2005 – 2009) by stage of development
Figure 193: Otsuka – recent deals (2005 – 2009) by therapy area
Figure 194: Recent Otsuka partnering deals (2003-2009) where contract document available
Figure 195: Pfizer – Dealmaking frequency 2000-2009
Figure 196: Pfizer - recent deals (2005-2009) by deal type
Figure 197: Pfizer - recent deals (2005 – 2009) by stage of development
Figure 198: Pfizer – recent deals (2005 – 2009) by therapy area
Figure 199: Recent Pfizer partnering deals (2003-2009) where contract document available
Figure 200: Procter & Gamble – Dealmaking frequency 2000-2009
Figure 201: Procter & Gamble - recent deals (2005-2009) by deal type
Figure 202: Procter & Gamble - recent deals (2005 – 2009) by stage of development
Figure 203: Procter & Gamble – recent deals (2005 – 2009) by therapy area
Figure 204: Recent Procter & Gamble partnering deals (2003-2009) where contract document available
Figure 205: Ratiopharm – Dealmaking frequency 2000-2009
Figure 206: Ratiopharm - recent deals (2005-2009) by deal type
Figure 207: Ratiopharm - recent deals (2005 – 2009) by stage of development
Figure 208: Ratiopharm – recent deals (2005 – 2009) by therapy area
Figure 209: Recent Ratiopharm partnering deals (2003-2009) where contract document available
Figure 210: Roche – Dealmaking frequency 2000-2009
Figure 211: Roche - recent deals (2005-2009) by deal type
Figure 212: Roche - recent deals (2005 – 2009) by stage of development
Figure 213: Roche – recent deals (2005 – 2009) by therapy area
Figure 214: Recent Roche partnering deals (2003-2009) where contract document available
Figure 215: Sanofi-Aventis – Dealmaking frequency 2000-2009
Figure 216: Sanofi-Aventis - recent deals (2005-2009) by deal type
Figure 217: Sanofi-Aventis - recent deals (2005 – 2009) by stage of development
Figure 218: Sanofi-Aventis – recent deals (2005 – 2009) by therapy area
Figure 219: Recent Sanofi-Aventis partnering deals (2003-2009) where contract document available
Figure 219: Schering Plough – Dealmaking frequency 2000-2009
Figure 220: Schering Plough - recent deals (2005-2009) by deal type
Figure 221: Schering Plough - recent deals (2005 – 2009) by stage of development
Figure 222: Schering Plough – recent deals (2005 – 2009) by therapy area
Figure 223: Recent Schering Plough partnering deals (2003-2009) where contract document available
Figure 225: Servier – Dealmaking frequency 2000-2009
Figure 226: Servier - recent deals (2005-2009) by deal type
Figure 227: Servier - recent deals (2005 – 2009) by stage of development
Figure 228: Servier – recent deals (2005 – 2009) by therapy area
Figure 229: Recent Servier partnering deals (2003-2009) where contract document available
Figure 230: Shire – Dealmaking frequency 2000-2009
Figure 231: Shire - recent deals (2005-2009) by deal type
Figure 232: Shire - recent deals (2005 – 2009) by stage of development

Figure 233: Shire – recent deals (2005 – 2009) by therapy area
Figure 234: Recent Shire partnering deals (2003-2009) where contract document available
Figure 235: Solvay – Dealmaking frequency 2000-2009
Figure 236: Solvay - recent deals (2005-2009) by deal type
Figure 237: Solvay - recent deals (2005 – 2009) by stage of development
Figure 238: Solvay – recent deals (2005 – 2009) by therapy area
Figure 239: Recent Solvay partnering deals (2003-2009) where contract document available
Figure 240: Takeda – Dealmaking frequency 2000-2009
Figure 241: Takeda - recent deals (2005-2009) by deal type
Figure 242: Takeda - recent deals (2005 – 2009) by stage of development
Figure 243: Takeda – recent deals (2005 – 2009) by therapy area
Figure 244: Recent Takeda partnering deals (2003-2009) where contract document available
Figure 245: Teva – Dealmaking frequency 2000-2009
Figure 246: Teva - recent deals (2005-2009) by deal type
Figure 247: Teva - recent deals (2005 – 2009) by stage of development
Figure 248: Teva – recent deals (2005 – 2009) by therapy area
Figure 249: Recent Teva partnering deals (2003-2009) where contract document available
Figure 250: UCB Group – Dealmaking frequency 2000-2009
Figure 251: UCB Group - recent deals (2005-2009) by deal type
Figure 252: UCB Group - recent deals (2005 – 2009) by stage of development
Figure 253: UCB Group – recent deals (2005 – 2009) by therapy area
Figure 254: Recent UCB Group partnering deals (2003-2009) where contract document available
Figure 255: Watson – Dealmaking frequency 2000-2009
Figure 256: Watson - recent deals (2005-2009) by deal type
Figure 257: Watson - recent deals (2005 – 2009) by stage of development
Figure 258: Watson – recent deals (2005 – 2009) by therapy area
Figure 259: Recent Watson partnering deals (2003-2009) where contract document available
Figure 260: Wyeth – Dealmaking frequency 2000-2009
Figure 261: Wyeth - recent deals (2005-2009) by deal type
Figure 262: Wyeth - recent deals (2005 – 2009) by stage of development
Figure 263: Wyeth – recent deals (2005 – 2009) by therapy area
Figure 264: Recent Wyeth partnering deals (2003-2009) where contract document available
Figure 265: Online partnering resources
Figure 266: Collaborative R&D and license agreement between GlaxoSmithKline and Supergen, November 2009



Order Form – Reports

Fax: +44 8703 305993

Email: orders@currentpartnering.com

Phone: +44 7896 656732

1. Select reports to purchase:

Title	Publication	Order Individual	Site licence
Partnering Agreements with Bigpharma	Feb 2010	<input type="checkbox"/> \$2,395	<input type="checkbox"/> \$7,995

2. Delivery details

Send reports as electronic PDF documents:

via email on a CD-Rom

print version of report - add: \$350

3. Contact details

Name	Title	Company
Address	City	State
Postcode	Country	Tel
Fax	Email	

4. Payment details

I enclose a cheque for \$_____ payable to Wildwood Ventures Ltd.

Please charge my card account:

Diners MasterCard Visa American Express

Name as it appears on the card: _____

Card number: _____ Expiry date: _____

CVV number: _____ (last three/four digits on the signature strip)

Signature: _____ Date: _____

Please bill me. I will pay by direct bank transfer.

Note: Reports sent only when payment received.

CurrentPartnering Reports

CurrentPartnering provides industry executives with partnering best practice and essential business intelligence. Further details about the range of services offered can be found at our website:

www.currentpartnering.com

Email: enquiry@currentpartnering.com

Telephone: +44 (0)7896 656732

Fax: +44 (0)8703 305993

Mail: CurrentPartnering
Wildwood Ventures Ltd.
Allanmere House
6 Hobgate
York
YO24 4HF
United Kingdom

All rights reserved.